| Deal value | $813M |
|---|---|
| Share of market cap | 40.3% |
| Share of annual revenue | 767.2% |
Key highlights
- Total potential transaction value reached $813 million including milestones
- Zymeworks to receive immediate $55 million upfront non-refundable payment
- Additional $40 million milestone payment due upon initiation of Phase 1b trial
- Roche gains exclusive worldwide rights to ZW209 and related DLL3 compounds
- Tiered royalties ranging from high-single digits to mid-teens on future net sales
What Is the Licensing Deal?
Roche has acquired exclusive global rights to develop and commercialize ZW209, a proprietary trispecific T-cell engager designed to target DLL3-expressing tumor cells. The agreement encompasses all research, manufacturing, and commercial activities for pharmaceutical products containing ZW209 or its derivatives. Under the technical terms, Zymeworks will remain responsible for conducting the Phase 1a monotherapy dose escalation trial at Roche's expense. Following this initial stage, Roche will assume full responsibility for the Phase 1b clinical trial and all subsequent global development and regulatory filings. The license becomes effective following clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
Down 7.0% since our story on 23 Oct: $28.44 when we broke it → $26.45 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $25.54 |
|---|---|
| 20 Oct | $26.91 |
| 21 Oct | $28.11 |
| 22 Oct | $28.44 |
| 23 Oct | $28.22 |
| 26 Oct | $28.37 |
| 27 Oct | $28.85 |
| 28 Oct | $28.90 |
| 29 Oct | $28.71 |
| 30 Oct | $28.61 |
| 2 Nov | $28.99 |
| 3 Nov | $30.13 |
| 4 Nov | $30.94 |
| 5 Nov | $28.73 |
| 6 Nov | $29.63 |
| 9 Nov | $30.81 |
| 10 Nov | $31.46 |
| 11 Nov | $29.07 |
| 12 Nov | $26.47 |
| 13 Nov | $26.24 |
| 16 Nov | $26.45 |
Licensing Terms
The financial framework provides Zymeworks with a $55 million upfront payment and a guaranteed $40 million payment upon the initiation of the Phase 1b trial. The company is also eligible to earn up to $718 million in additional research, development, and commercial milestones. Beyond these cash payments, Zymeworks will receive tiered royalties on global net sales, with rates spanning from high-single digits to the mid-teens. These royalties are protected by a patent estate extending into the 2040s. For a five-year period or until the start of a Phase 3 study, Zymeworks is restricted from developing competing T-cell engagers targeting DLL3-expressing cells.
Strategic Fit
This collaboration follows Zymeworks' strategy of advancing differentiated therapeutic candidates internally while selectively partnering programs to mitigate clinical risk. By integrating Roche's manufacturing and commercial infrastructure, the company aims to accelerate ZW209's reach across various lung cancer indications. This deal complements Zymeworks' broader research portfolio, which includes multispecific T-cell engagers for solid and hematological tumors. The agreement also builds on recent financial moves, such as the $250 million royalty-backed note financing secured from Royalty Pharma in March 2026 and a research partnership with Gandeeva Therapeutics signed in June 2026.
Business Overview
- Headquartered in Delaware with specialized R&D operations in Vancouver
- Focused on multifunctional biotherapeutics for oncology and autoimmune diseases
- Updated 2026 revenue guidance project totals between $278 million and $292 million
- Anticipates $100 million milestone payment from Royalty Pharma in Q1 2027
- Maintains a robust portfolio of multispecific antibody platforms and AIID programs
Management Perspective
“This collaboration allows us to continue advancing ZW209 through its initial clinical development while leveraging Roche’s complementary capabilities to accelerate and expand its development across indications and treatment settings.”
| Date | Announcement | Amount |
|---|---|---|
| 18 Jun 2026 | Research partnership with Gandeeva Therapeutics to accelerate antibody drug discovery using cryo-EMSource: gandeeva.com | – |
| 02 Mar 2026 | Royalty-backed note financing agreement with Royalty Pharma secured by 30% of Ziihera royalty cash flowsSource: ir.zymeworks.com | $250.0 Million |
| 30 Oct 2025 | Three-Party Royalty Payment Agreement with BeOne Medicines and BeOne Pharmaceutical (Suzhou)Source: SEC filing | – |
Management commentary
“The agreement also reflects our broader strategy of generating innovative programs through our R&D engine and partnering selected assets in ways that share development risk while preserving meaningful participation in their future success.”
| Share price | $28.44 |
|---|---|
| Market cap | $2.0B |
| Revenue (annual) | $106M |
| 1-month price change | +3.17% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Zymeworks Inc. announcing an exclusive global license and collaboration agreement with Roche for ZW209.
Track Zymeworks Inc. live
Get the next Zymeworks Inc. SEC filing seconds after it lands.



